[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:idiopathic-pulmonary-fibrosis":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":277,"states":278},"Idiopathic Pulmonary Fibrosis",44,33,[8,16,22,28,35,41,48,54,59,65,71,77,83,90,96,102,108,114,120,126,132,138,144,150,156,162,168,174,180,186,191,197,203,210,217,222,228,233,239,245,252,258,264,270],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06325696","H01 in Adults With Interstitial Lung Disease (The SOLIS Study)",[12],"Phase 2","RECRUITING","2026-08-26T02:19:28.327680Z","2026-07-30T01:46:14.464030Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT07036523","A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment",[12],"2026-08-26T02:16:21.385056Z","2026-07-30T01:46:14.414849Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT06967805","WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)",[12],"2026-08-26T02:17:16.980188Z","2026-06-16T05:54:07.929692Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":33,"content_modified":34},"NCT06238622","A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast",[32],"Phase 3","2026-08-26T02:17:28.381459Z","2026-05-05T02:43:29.045665Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT05571059","Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)",[12],"2026-08-26T02:19:19.975067Z","2026-05-05T02:43:29.029319Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":46,"content_modified":47},"NCT07036029","NAL ER IPF Respiratory Function and Safety Study",[45],"Phase 1","2026-08-03T03:30:23.638222Z","2026-05-05T02:43:27.838727Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT05975983","Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis",[12],"2026-08-26T02:16:13.426928Z","2026-05-05T02:43:27.624733Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":33,"content_modified":58},"NCT06968845","A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis",[12],"2026-05-05T02:43:27.424647Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":63,"content_modified":64},"NCT07230288","Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis",[12],"2026-08-26T02:16:15.345907Z","2026-05-05T02:43:27.283043Z",{"nct_id":66,"title":67,"phases":68,"status":13,"updated_at":69,"content_modified":70},"NCT05988463","Dose-Escalation Study of Artesunate Patients With IPF",[45],"2026-08-26T02:16:38.053590Z","2026-05-05T02:43:26.954479Z",{"nct_id":72,"title":73,"phases":74,"status":13,"updated_at":75,"content_modified":76},"NCT06567717","Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis",[12],"2026-08-26T02:18:12.612955Z","2026-04-29T02:57:57.064629Z",{"nct_id":78,"title":79,"phases":80,"status":13,"updated_at":81,"content_modified":82},"NCT06951217","An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)",[12],"2026-08-26T02:16:58.658552Z","2026-04-29T02:57:57.062755Z",{"nct_id":84,"title":85,"phases":86,"status":13,"updated_at":88,"content_modified":89},"NCT03500731","Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure",[87],"Phase 1\u002FPhase 2","2026-08-26T02:16:24.135291Z","2026-05-05T02:43:26.906541Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT07002034","RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses",[12],"2026-08-26T02:17:32.059863Z","2026-05-05T02:43:28.496200Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT06940427","Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis",[12],"2026-08-26T02:18:54.586325Z","2026-05-05T02:43:28.621525Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT04362644","Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis",[45],"2026-08-26T02:18:11.042248Z","2026-05-05T02:43:28.534210Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT04778046","Pulmonary Hypertension SOLAR",[12],"2026-08-26T02:17:49.709549Z","2026-05-05T02:43:26.974534Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT07671911","Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets",[32],"2026-08-26T02:19:08.862440Z","2026-07-19T19:36:05.144415Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":124,"content_modified":125},"NCT07284602","Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)",[32],"2026-08-26T02:15:37.042762Z","2026-07-19T19:36:05.137855Z",{"nct_id":127,"title":128,"phases":129,"status":13,"updated_at":130,"content_modified":131},"NCT06162884","Single Time Point Prediction as Earlier Diagnosis of Progressive Pulmonary Fibrosis",[],"2026-08-26T02:18:51.833592Z","2026-07-05T05:32:16.745648Z",{"nct_id":133,"title":134,"phases":135,"status":13,"updated_at":136,"content_modified":137},"NCT07652658","A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.",[12],"2026-08-26T02:17:39.048487Z","2026-06-17T19:21:16.684819Z",{"nct_id":139,"title":140,"phases":141,"status":13,"updated_at":142,"content_modified":143},"NCT06323876","The Role of Quantitative CT and Radiomic Biomarkers for Precision Medicine in Pulmonary Fibrosis",[],"2026-08-26T02:17:46.653867Z","2026-05-13T02:55:06.435394Z",{"nct_id":145,"title":146,"phases":147,"status":13,"updated_at":148,"content_modified":149},"NCT03437486","Mechanisms of Familial Pulmonary Fibrosis",[],"2026-08-26T02:18:47.742071Z","2026-05-13T02:55:06.126381Z",{"nct_id":151,"title":152,"phases":153,"status":13,"updated_at":154,"content_modified":155},"NCT03478553","The Genetics of Pulmonary Fibrosis",[],"2026-08-26T02:16:55.892527Z","2026-05-13T02:55:06.125206Z",{"nct_id":157,"title":158,"phases":159,"status":13,"updated_at":160,"content_modified":161},"NCT03418350","The Role of Laryngopharyngeal Reflux in IPF",[],"2026-08-26T02:15:38.131683Z","2026-05-13T02:55:06.123500Z",{"nct_id":163,"title":164,"phases":165,"status":13,"updated_at":166,"content_modified":167},"NCT01915511","Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry",[],"2026-08-26T02:19:10.436356Z","2026-05-13T02:55:06.079810Z",{"nct_id":169,"title":170,"phases":171,"status":13,"updated_at":172,"content_modified":173},"NCT00373841","Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)",[],"2026-08-26T02:16:18.872924Z","2026-05-13T02:55:06.034909Z",{"nct_id":175,"title":176,"phases":177,"status":13,"updated_at":178,"content_modified":179},"NCT05382572","Pulmonary Fibrosis Foundation Community Registry",[],"2026-08-26T02:17:41.695983Z","2026-05-13T02:55:06.302948Z",{"nct_id":181,"title":182,"phases":183,"status":13,"updated_at":184,"content_modified":185},"NCT00470327","A Study of the Natural Progression of Interstitial Lung Disease (ILD)",[],"2026-08-26T02:16:22.235886Z","2026-05-13T02:55:06.035938Z",{"nct_id":187,"title":188,"phases":189,"status":13,"updated_at":160,"content_modified":190},"NCT05798923","LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)",[12],"2026-07-19T19:36:05.138939Z",{"nct_id":192,"title":193,"phases":194,"status":13,"updated_at":195,"content_modified":196},"NCT05392881","Interstitial Lung Disease Research Unit Biobank",[],"2026-08-26T02:18:46.948970Z","2026-05-13T02:55:06.304070Z",{"nct_id":198,"title":199,"phases":200,"status":13,"updated_at":201,"content_modified":202},"NCT01776398","Collection of Airway, Blood and\u002For Urine Specimens From Subjects for Research Studies",[],"2026-08-26T02:17:30.961790Z","2026-05-13T02:55:06.079817Z",{"nct_id":204,"title":205,"phases":206,"status":13,"updated_at":208,"content_modified":209},"NCT06853145","Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis",[207],"Early Phase 1","2026-08-26T02:19:11.399072Z","2026-05-05T02:43:29.196955Z",{"nct_id":211,"title":212,"phases":213,"status":214,"updated_at":215,"content_modified":216},"NCT07679893","Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis",[12],"NOT_YET_RECRUITING","2026-08-03T01:02:33.016872Z","2026-07-05T03:45:20.440817Z",{"nct_id":218,"title":219,"phases":220,"status":214,"updated_at":178,"content_modified":221},"NCT07674745","Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis",[12],"2026-07-05T03:45:20.434634Z",{"nct_id":223,"title":224,"phases":225,"status":214,"updated_at":226,"content_modified":227},"NCT07441408","Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis",[32],"2026-08-26T02:18:30.351130Z","2026-06-17T02:29:30.055527Z",{"nct_id":229,"title":230,"phases":231,"status":214,"updated_at":63,"content_modified":232},"NCT07520110","Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis",[32],"2026-05-05T02:43:27.405987Z",{"nct_id":234,"title":235,"phases":236,"status":214,"updated_at":237,"content_modified":238},"NCT07613216","A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension",[],"2026-08-26T02:16:36.513735Z","2026-05-29T15:36:40.232556Z",{"nct_id":240,"title":241,"phases":242,"status":214,"updated_at":243,"content_modified":244},"NCT07673237","Remote Evaluation and Surveillance of Patients With Interstitial Lung Disease: Transforming ILD Care Delivery With Remote Monitoring",[],"2026-08-26T02:15:03.757872Z","2026-07-05T03:45:20.433669Z",{"nct_id":246,"title":247,"phases":248,"status":249,"updated_at":250,"content_modified":251},"NCT04905693","Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease",[32],"ENROLLING_BY_INVITATION","2026-08-26T02:15:56.561131Z","2026-07-05T18:42:10.714814Z",{"nct_id":253,"title":254,"phases":255,"status":249,"updated_at":256,"content_modified":257},"NCT04896138","University of Virginia Natural History Study",[],"2026-08-26T02:16:51.982021Z","2026-07-05T18:42:10.714751Z",{"nct_id":259,"title":260,"phases":261,"status":262,"updated_at":46,"content_modified":263},"NCT05389215","Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF",[12],"ACTIVE_NOT_RECRUITING","2026-05-05T02:43:28.672541Z",{"nct_id":265,"title":266,"phases":267,"status":262,"updated_at":268,"content_modified":269},"NCT06241560","A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood",[12],"2026-08-03T03:29:04.388436Z","2026-05-05T02:35:31.897089Z",{"nct_id":271,"title":272,"phases":273,"status":274,"updated_at":275,"content_modified":276},"NCT05866198","Physical Activity and Quality of Life in Fibrotic Lung Diseases After Initiating Anti-fibrotic Therapy and Pulmonary Rehabilitation",[],"UNKNOWN","2026-08-03T02:27:16.454962Z","2026-05-05T02:43:28.535343Z",[],[279,283,287,290,294,298,301,305,308,311,315,319,322,325,328,332,335,339,342,345,349,352,356,359],{"state":280,"count":281,"slug":282},"Pennsylvania",17,"pennsylvania",{"state":284,"count":285,"slug":286},"California",16,"california",{"state":288,"count":285,"slug":289},"North Carolina","north-carolina",{"state":291,"count":292,"slug":293},"Florida",15,"florida",{"state":295,"count":296,"slug":297},"Alabama",14,"alabama",{"state":299,"count":296,"slug":300},"Texas","texas",{"state":302,"count":303,"slug":304},"Illinois",12,"illinois",{"state":306,"count":303,"slug":307},"Kansas","kansas",{"state":309,"count":303,"slug":310},"Virginia","virginia",{"state":312,"count":313,"slug":314},"New York",11,"new-york",{"state":316,"count":317,"slug":318},"Colorado",10,"colorado",{"state":320,"count":317,"slug":321},"Michigan","michigan",{"state":323,"count":317,"slug":324},"South Carolina","south-carolina",{"state":326,"count":317,"slug":327},"Tennessee","tennessee",{"state":329,"count":330,"slug":331},"Arizona",9,"arizona",{"state":333,"count":330,"slug":334},"Massachusetts","massachusetts",{"state":336,"count":337,"slug":338},"Missouri",8,"missouri",{"state":340,"count":337,"slug":341},"Ohio","ohio",{"state":343,"count":337,"slug":344},"Utah","utah",{"state":346,"count":347,"slug":348},"Georgia",7,"georgia",{"state":350,"count":347,"slug":351},"Wisconsin","wisconsin",{"state":353,"count":354,"slug":355},"Maryland",6,"maryland",{"state":357,"count":354,"slug":358},"Minnesota","minnesota",{"state":360,"count":354,"slug":361},"Oregon","oregon"]